This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted
outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and
pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.